SVF
Level D· Preclinical EvidenceLaboratory Study

Engineering Adaptive Immunity in 3D: A Patient-Specific Lymphoid Model Using Stromal Networks and Peripheral Blood Mononuclear Cells.

ElGindi M., Karaman S., Teo J.

Laboratory Study on Chronic Inflammation, Autoimmune Research, published in Adv Sci (Weinh) (2026) — summary generated from the PubMed abstract.

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Laboratory Study
Journal
Adv Sci (Weinh) (2026)
Country
Germany
Reported sample size
—
PMID
41400407
DOI
10.1002/advs.202513245

Abstract (original English)

Tertiary lymphoid organs (TLOs) are non-encapsulated immune structures that emerge in response to chronic inflammation, orchestrating local adaptive immune responses. However, recapitulating their complexity in vitro remains challenging due to the difficulty in generating physiologically relevant stromal-immune interactions. Here, a 3D lymphoid tissue model is presented, engineered using human adipose-derived stem cells (ADSCs) differentiated into fibroblastic reticular cell (FRC)-like populations within collagen matrices. Differentiation is induced using TNF-α and LT-α, with or without IL-4, generating two stromal phenotypes: FRC P1 and FRC P2 . These subsets exhibit matrix remodeling, distinct transcriptional signatures, and surface markers consistent with lymph node-resident T cell reticular and follicular dendritic cell subsets. Upon co-culture with peripheral blood mononuclear cells (PBMCs) and SARS-CoV-2 S1-primed mature dendritic cells, the model supports antigen-specific B cell activation and cytokine environments indicative of Th1 or Th2 polarization. FRC P1 favors B cell support and IgM secretion, whereas FRC P2 promotes dendritic cell activation and Th1-type chemokine expression. This platform demonstrates the functional diversification of stem cell-derived FRC-like subsets and their role in orchestrating immune microenvironments. It enables investigation of lymphoid

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence comes from animal or laboratory studies and has not been confirmed in humans.

How we grade evidence
HumansAdaptive ImmunityLeukocytes, MononuclearCOVID-19Cell DifferentiationStromal CellsSARS-CoV-2Coculture TechniquesB-LymphocytesDendritic Cells
Face & SkinChronic InflammationAutoimmune Research
View on PubMedDOI

Related research